Regeneron Pharmaceuticals Stock Price, News & Analysis

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a biotechnology company that invents, develops and commercializes medicines for people with serious diseases. According to the company, its medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases. Many of its approved treatments and product candidates were discovered and developed in its own laboratories.

Core business and therapeutic focus

Regeneron operates in the pharmaceutical preparation manufacturing industry, with a focus on biologic medicines. The company describes itself as founded and led by physician-scientists, emphasizing its ability to translate science into medicine. Its marketed products and clinical pipeline span multiple therapeutic areas, including ophthalmology, immunology, oncology, hematology, cardiovascular and metabolic disease, infectious disease and rare genetic conditions.

The company has several marketed products. These include medicines for eye disease such as EYLEA and EYLEA HD (aflibercept), which are used in conditions like wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, macular edema following retinal vein occlusion and retinopathy of prematurity. Regeneron also co-develops Dupixent (dupilumab) with Sanofi in immunology, which is approved in multiple countries for indications such as atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, chronic obstructive pulmonary disease and bullous pemphigoid in specific age groups.

In oncology, Regeneron markets Libtayo (cemiplimab), a PD‑1 inhibitor approved in various regions for certain patients with cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer and cervical cancer, and as an adjuvant treatment for cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation in the European Union and the United States. The company also markets Lynozyfic (linvoseltamab), a BCMAxCD3 bispecific antibody approved for certain adults with relapsed or refractory multiple myeloma in the United States and European Union.

Research platforms and proprietary technologies

Regeneron highlights its proprietary technology platforms as central to its business model. The VelociSuite family of technologies, including VelocImmune, is used to produce optimized fully human antibodies and new classes of bispecific antibodies. VelocImmune is based on a genetically engineered mouse platform with a genetically humanized immune system. The company states that this technology has been used to create a substantial proportion of original, fully human monoclonal antibodies approved by the U.S. Food and Drug Administration, including Dupixent, Libtayo, Praluent, Kevzara, Evkeeza, Inmazeb and Veopoz, as well as the REGEN‑COV antibody combination that was authorized during the COVID‑19 pandemic until 2024.

Regeneron also operates the Regeneron Genetics Center, which provides data-powered insights to support target identification and development of genetic medicine platforms. In addition, the company is advancing investigational programs in gene editing and genetic medicines, such as a collaboration with Tessera Therapeutics to develop TSRA‑196, an in vivo gene editing program for alpha‑1 antitrypsin deficiency.

Key marketed products and programs

In ophthalmology, Regeneron developed EYLEA and EYLEA HD (aflibercept) for serious retinal vascular diseases. EYLEA HD 8 mg has been approved in the United States for wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and macular edema following retinal vein occlusion, with dosing intervals that can extend beyond monthly after initial treatment. EYLEA and EYLEA HD are jointly developed with Bayer, with Regeneron holding exclusive rights in the United States and Bayer marketing outside the United States.

Dupixent, invented using VelocImmune technology and jointly developed with Sanofi, is a fully human monoclonal antibody that inhibits interleukin‑4 and interleukin‑13 signaling, which are described as key drivers of type 2 inflammation. Dupixent has received regulatory approvals in more than 60 countries in one or more indications, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, chronic obstructive pulmonary disease and bullous pemphigoid in defined patient populations. Regeneron and Sanofi continue to study dupilumab in additional type 2 inflammatory and allergic diseases in Phase 3 trials.

In hematology and oncology, Regeneron is advancing a broad portfolio. Lynozyfic (linvoseltamab) is a BCMAxCD3 bispecific antibody designed to bridge BCMA on multiple myeloma cells with CD3 on T cells to facilitate T‑cell activation and cancer-cell killing. It is approved for certain adults with relapsed or refractory multiple myeloma and is being studied as monotherapy and in combinations in earlier lines of therapy and precursor plasma cell disorders. Odronextamab, a CD20xCD3 bispecific antibody, is approved in the European Union as Ordspono for relapsed or refractory follicular lymphoma or diffuse large B‑cell lymphoma after at least two prior systemic therapies and is being evaluated in a broad Phase 3 program in earlier lines of B‑cell non‑Hodgkin lymphomas.

Regeneron is also developing treatments for rare blood disorders and cardiovascular disease. Its hematology research includes bispecific antibodies and other modalities for conditions such as paroxysmal nocturnal hemoglobinuria and severe aplastic anemia, including investigational agents like pozelimab plus cemdisiran and REGN7257. In cardiovascular medicine, the company is advancing two mechanistically distinct factor XI antibodies, REGN7508Cat and REGN9933A2, designed to provide anticoagulation with distinct bleeding risk profiles. Phase 2 trials in patients undergoing total knee replacement demonstrated robust anti‑clotting effects consistent with their design, and Phase 3 and additional Phase 2 trials are underway in venous thromboembolism prevention and atrial fibrillation.

Collaborations and partnerships

Regeneron’s business model includes strategic collaborations that complement its internal capabilities. The company has global collaboration agreements with Sanofi for dupilumab and other antibodies, with Bayer for EYLEA and EYLEA HD outside the United States, with Alnylam for RNAi-based approaches, and with Tessera Therapeutics for gene editing in alpha‑1 antitrypsin deficiency. These collaborations can involve shared development responsibilities, cost sharing and profit sharing, as described in the Tessera agreement where worldwide development costs and potential future profits for TSRA‑196 will be shared equally.

Geographic and regulatory footprint

Regeneron is incorporated in New York and lists its principal executive offices in Tarrytown, New York in its SEC filings. Its products have obtained approvals from regulators in the United States, the European Union, Japan and other countries, depending on the specific medicine and indication. The company’s SEC filings, such as Form 8‑K reports, show that it regularly reports quarterly and annual financial and operating results and provides updates on collaboration-related charges and other financial items.

Innovation and pipeline breadth

The company emphasizes that oncology assets in clinical development comprise a significant portion of its pipeline, including checkpoint inhibitors, bispecific antibodies and costimulatory bispecific antibodies. Regeneron’s hematology portfolio includes programs in multiple myeloma, lymphoma and rare blood disorders, with data presented at major scientific meetings such as the American Society of Hematology Annual Meeting. Its ophthalmology development program includes efforts in geographic atrophy, glaucoma and inherited retinal diseases, and its genetic medicine initiatives extend to gene editing and gene-knockout approaches.

Across these areas, Regeneron’s strategy, as described in its public communications, is to apply its biology expertise, proprietary platforms and genetics capabilities to discover and develop medicines across a broad spectrum of serious diseases.

Frequently asked questions about Regeneron Pharmaceuticals (REGN)

• What does Regeneron Pharmaceuticals do?
  Regeneron Pharmaceuticals is a biotechnology company that invents, develops and commercializes medicines for serious diseases. Its medicines and pipeline target eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases.
• In which therapeutic areas does Regeneron have marketed products?
  Regeneron has marketed products in ophthalmology (for example, EYLEA and EYLEA HD for retinal diseases), immunology (Dupixent for multiple type 2 inflammatory conditions), oncology (Libtayo for several cancers and Lynozyfic for relapsed or refractory multiple myeloma) and cardiovascular and metabolic disease (such as Praluent for LDL cholesterol lowering, as described in the Polygon profile).
• What technologies underpin Regeneron’s drug discovery and development?
  Regeneron uses proprietary VelociSuite technologies, including VelocImmune, to generate optimized fully human antibodies and bispecific antibodies. It also uses data from the Regeneron Genetics Center and genetic medicine platforms to identify targets and approaches to potentially treat or cure diseases.
• How is Dupixent related to Regeneron?
  Dupixent (dupilumab) was invented using Regeneron’s VelocImmune technology and is jointly developed by Regeneron and Sanofi under a global collaboration. It is a fully human monoclonal antibody that inhibits interleukin‑4 and interleukin‑13 signaling and has been approved in more than 60 countries in one or more indications driven in part by type 2 inflammation.
• What is EYLEA HD and how does it fit into Regeneron’s portfolio?
  EYLEA HD (aflibercept) Injection 8 mg is a higher-dose formulation of aflibercept approved in the United States for wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and macular edema following retinal vein occlusion. It was developed to achieve efficacy and safety comparable to EYLEA with fewer injections and is part of Regeneron’s ophthalmology portfolio.
• What is Libtayo and for which patients is it approved?
  Libtayo (cemiplimab) is a fully human monoclonal antibody targeting the PD‑1 receptor on T cells. It is approved in more than 30 countries in one or more indications, including certain adult patients with advanced or high-risk cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and recurrent or metastatic cervical cancer. In the European Union and United States, it is also approved as an adjuvant treatment for cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.
• What is Lynozyfic and what disease does it address?
  Lynozyfic (linvoseltamab) is a fully human BCMAxCD3 bispecific antibody invented using VelocImmune technology. It is designed to bridge BCMA on multiple myeloma cells with CD3 on T cells to facilitate T‑cell activation and cancer-cell killing and is approved to treat certain adults with relapsed or refractory multiple myeloma in the United States and European Union.
• How does Regeneron use genetics in its research?
  Regeneron states that it uses data-powered insights from the Regeneron Genetics Center and pioneering genetic medicine platforms to identify innovative targets and complementary approaches. This includes collaborations such as the TSRA‑196 gene editing program for alpha‑1 antitrypsin deficiency with Tessera Therapeutics.
• Where is Regeneron incorporated and on which exchange does it trade?
  Regeneron Pharmaceuticals, Inc. is incorporated in New York and its common stock trades on NASDAQ under the ticker symbol REGN, as noted in multiple company press releases and SEC filings.
• How does Regeneron communicate financial results?
  Regeneron files current reports on Form 8‑K with the U.S. Securities and Exchange Commission to furnish press releases announcing its quarterly and annual financial and operating results. Examples include Form 8‑K filings reporting results for quarters ended June 30, 2025 and September 30, 2025.